Aclaris Therapeutics (NASDAQ: ACRS) reported Q3 EPS of ($0.30), $0.09 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $19.02 million versus the consensus estimate of $1.62 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.